Secondary-progressive Multiple Sclerosis
7
0
1
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
28.6%
2 terminated out of 7 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients
Behavioural Activation for Low Mood in Multiple Sclerosis
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition